文献速递甲状腺核医学肿瘤 PET/CT核素与放射性配体治疗

转移性低分化甲状腺癌中18F-FDG、68Ga-DOTATATE与68Ga-PSMA PET/CT摄取异质性分布一例

Metastatic Poorly Differentiated Thyroid Cancer With Heterogeneous Distribution of 18F-FDG, 68Ga-DOTATATE, and 68Ga-PSMA on PET/CT.
PubMed 文献 · Clin Nucl Med · 2021-01-01

本文报道一例55岁男性低分化转移性甲状腺癌患者,18F-FDG PET/CT示碘难治性多发转移,遂行68Ga-DOTATATE与68Ga-PSMA PET/CT评估DOTATATE或PSMA导向核素治疗机会。三种PET/CT显像检出不同的肿瘤摄取模式,展示了肿瘤异质性。

要点

  • 低分化转移性甲状腺癌侵袭性强且罕见,可表现为碘难治性多发转移。
  • 18F-FDG PET/CT示碘难治性转移后,可进一步行68Ga-DOTATATE与68Ga-PSMA PET/CT评估核素治疗机会。
  • 同一患者三种PET/CT显像呈现不同肿瘤摄取模式,体现肿瘤异质性。

核心结论

  • 低分化转移性甲状腺癌患者中18F-FDG、68Ga-DOTATATE与68Ga-PSMA PET/CT可呈现不同的肿瘤摄取模式,体现肿瘤异质性。

研究设计与样本

  • 个案报道:一例55岁男性低分化转移性甲状腺癌患者。

主要发现

  • 18F-FDG PET/CT显示碘难治性多发转移。
  • 68Ga-DOTATATE与68Ga-PSMA PET/CT用于评估DOTATATE或PSMA导向核素治疗的机会。
  • 18F-FDG、68Ga-DOTATATE与68Ga-PSMA PET/CT检出不同的肿瘤摄取模式。

临床怎么用

  • 对碘难治性低分化转移性甲状腺癌,可考虑补充68Ga-DOTATATE与68Ga-PSMA PET/CT以评估靶向核素治疗机会。

局限性

  • 本文为单例个案报道,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present a case of a 55-year-old man with a history of poorly differentiated metastatic thyroid cancer, which is rare and shows aggressive behavior. The patient had radioactive iodine-negative multiple metastasis on 18F-FDG PET/CT, therefore 68Ga-DOTATATE and 68Ga-PSMA PET/CT were performed whether an opportunity exist for DOTATATE or PSMA-directed radionuclide therapy. Different patterns of tumoral uptakes were detected on 18F-FDG, 68Ga-DOTATATE, and 68Ga-PSMA PET/CT, as a demonstration of tumor heterogeneity.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Civan C, Isik EG, Simsek DH, et al. Metastatic Poorly Differentiated Thyroid Cancer With Heterogeneous Distribution of 18F-FDG, 68Ga-DOTATATE, and 68Ga-PSMA on PET/CT. Clin Nucl Med. 2021. PMID: 33156050. doi:10.1097/RLU.0000000000003362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。